Curcumin and Piperine in Reducing Inflammation for Ureteral Stent-Induced Symptoms in Patients With Cancer

Inclusion Criteria: * Ureteral stent in place at study registration * Patient reports pain, spasms, or urgency symptoms after stent placement, which are thought to be unrelated to other causes as per the patient or healthcare provider or both (documentation in the medical record is unnecessary) * Ability to complete English language questionnaires by themselves or with assistance * After the week-long study treatment, participants must be willing to return to the enrolling institution for a follow-up visit * Willingness to provide mandatory 24 hour urine collection samples for research purposes * Able to swallow supplements * Patient must have either a history of cancer or active cancer * Registration \>= 7 days after placement of a new stent or \>= 3 days after a stent exchange * Willingness to refrain from grapefruit juice for 7 days prior to and for 7 days during the study Exclusion Criteria: * Receiving warfarin at registration * Active cholecystitis * Taking any of the following drugs at the time of study participation: epidermal growth factor receptor inhibitor, topoisomerase 1 inhibitor (camptothecin, irinotecan); buspirone, benzodiazepines, zolpidem, calcium channel blockers (such as felodipine, nifedipine, verapamil); digoxin or quinidine; codeine or fentanyl; phenytoin, propranolol, rifampin, or theophylline * History of alcohol abuse